HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders
Home » HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders
HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders2019-08-282019-08-30http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.